Lupus does not directly cause shingles, but it roughly doubles the risk of developing it. A large U.S. study found that people with systemic lupus erythematosus (SLE) developed shingles at a rate of about 20 per 1,000 patient-years, compared to fewer than 6 per 1,000 in matched controls without autoimmune disease. The reasons stretch beyond the disease itself into the medications used to treat it, and the relationship between the two conditions turns out to be a two-way street that complicates management in ways most patients never hear about.
How Much Higher Is the Risk, Really?
Shingles, or herpes zoster, happens when the varicella-zoster virus that caused your childhood chickenpox wakes up from dormancy in nerve tissue. In the general population, the lifetime risk is significant but spread across decades. In lupus, the timeline compresses. A 2025 retrospective study using U.S. insurance claims data compared over 60,000 SLE patients with a million matched controls and found that the adjusted incidence rate was roughly 1.9 times higher in the lupus group overall. Among SLE patients who had no other immune-compromising conditions, the rate was still about 1.5 times higher than the general population, at around 14 per 1,000 patient-years.1PubMed Central. Burden of herpes zoster among patients with systemic lupus erythematosus in the USA
That roughly two-fold increase holds up across multiple studies and countries. It is large enough that rheumatologists consider shingles prevention a standard part of lupus care, not an afterthought. And the risk is not evenly distributed among all lupus patients. Certain subgroups face much steeper odds, depending on their disease activity, their blood counts, and the drugs they take.
Why Lupus Weakens Your Defense Against the Virus
Your immune system normally keeps varicella-zoster virus locked down through a branch of immunity that relies on T cells, specifically a type called CD4+ T cells. These cells recognize pieces of the virus and mount a response that holds it in check inside nerve ganglia. In lupus, that cellular response is measurably impaired. When researchers exposed blood samples from SLE patients to varicella-zoster virus in the lab, they found that the lupus patients produced fewer of the immune signaling molecules needed to suppress the virus and showed reduced CD4+ T cell proliferation compared to healthy controls.2PubMed. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases
This is not just about having a weaker immune system in some vague sense. Lupus specifically disrupts the kind of immunity that matters for keeping latent viruses in check, while often leaving other immune functions intact or even overactive. The disease is, at its core, a disorder of immune misdirection: the immune system attacks the body’s own tissues with great enthusiasm while sometimes neglecting the surveillance duties that keep dormant infections silent.
One measurable sign of this vulnerability is lymphopenia, a drop in the number of lymphocytes circulating in the blood. A study of SLE patients found that lymphopenia carried more than a four-fold increase in the odds of developing shingles. Even more striking, it was the only independent predictor of complicated shingles, raising that risk more than fifteen-fold.3PubMed Central. Herpes zoster in patients with systemic lupus erythematosus: Clinical features, complications and risk factors Lymphopenia is common in active lupus, affecting a substantial fraction of patients during flares, so this risk factor is not rare or theoretical.
The Role of Lupus Medications
Here is where the picture gets tangled: the drugs that control lupus also suppress the very immune responses that keep shingles at bay. Teasing apart how much of the increased shingles risk comes from lupus itself versus from its treatment is genuinely difficult, and the honest answer is that both contribute.
Glucocorticoids (steroids like prednisone) are the best-studied offenders. Multiple studies have found a dose-dependent relationship, meaning higher steroid doses translate into higher shingles risk. One study found that high-dose glucocorticoids carried more than four times the odds of developing shingles.3PubMed Central. Herpes zoster in patients with systemic lupus erythematosus: Clinical features, complications and risk factors A nationwide case-control study confirmed that the shingles risk was strongly dose-dependent for oral corticosteroids and that patients on multiple immunosuppressive drugs simultaneously faced the highest risk.4PubMed. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study
Other immunosuppressants carry their own shingles risk. In patients with lupus nephritis (kidney involvement), both mycophenolate mofetil and cyclophosphamide were linked to shingles reactivation during induction therapy, with the risk scaling alongside the dose of each drug.5PubMed. Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies The practical takeaway from that research was to use the lowest effective doses of these drugs when possible, a principle easy to state but hard to follow when kidney function is at stake.
Newer treatments have added new concerns. JAK inhibitors, an increasingly used class of drugs for autoimmune conditions, and anifrolumab, a biologic approved specifically for lupus, have both been associated with shingles rates higher than those seen with older immunosuppressants. This is on top of the already elevated baseline risk that lupus patients carry.6Current Treatment Options in Rheumatology. Risk of Herpes Zoster and Opportunistic Infections with Treatments for Autoimmune Rheumatic Disease For patients and their doctors, this means that starting certain newer therapies should prompt a serious conversation about shingles prevention, ideally before the first dose.
Shingles Can Trigger Lupus Flares
Most discussions of lupus and shingles focus on lupus raising the risk of shingles. Fewer mention that the relationship runs in both directions. A matched cohort study found that SLE patients who developed a varicella-zoster virus infection were far more likely to experience a lupus flare afterward. About a third of patients flared after a shingles episode, compared to roughly one in ten in matched controls who did not have the infection. After adjusting for multiple confounders including age, baseline disease activity, and medications, shingles was independently associated with roughly a four-fold increase in flare risk.7BMJ. Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study
This creates a vicious cycle. Lupus and its treatment predispose you to shingles. Shingles then destabilizes lupus, potentially leading to the kind of flare that requires more aggressive immunosuppression, which in turn raises the risk of another shingles episode down the line. Infections in general can trigger lupus flares, but the researchers specifically tested whether urinary tract infections had the same effect and found they did not, suggesting something particular about the immune activation caused by herpes zoster reactivation.
Complications Hit Harder in Lupus
Shingles is not just a painful rash that resolves in a few weeks. Its most feared complication is postherpetic neuralgia, the burning, stabbing nerve pain that persists for months or years after the rash clears. In the general population, about 10 to 20 percent of shingles patients develop it. In lupus, the numbers are worse. A large Taiwanese cohort study of over 34,000 shingles patients found that those with SLE were more than twice as likely to develop postherpetic neuralgia compared to shingles patients without lupus.8PubMed Central. A systematic review and meta-analysis of risk factors for postherpetic neuralgia
One study of lupus patients with shingles found postherpetic neuralgia in about 20 percent and a recurrence rate of about 8 percent.9Journal of Clinical Rheumatology. Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus Recurrence may sound low, but in the general population shingles recurrence is unusual enough that many people assume it cannot happen twice. For lupus patients, the combination of ongoing immune suppression and the factors that triggered the first episode makes recurrence a real concern.
Beyond postherpetic neuralgia, shingles in immunosuppressed patients carries a risk of disseminated disease, where the virus spreads beyond a single dermatome to involve the skin widely, or invades the eyes, brain, or other organs. Bacterial superinfection of the blistered skin is another recognized complication. As noted earlier, lymphopenia was the strongest independent predictor of complicated shingles in one study, raising the odds dramatically.
When Lupus Mimics Shingles
One clinical wrinkle that even some physicians stumble over: lupus can produce skin eruptions that look remarkably similar to shingles. A case report described a child with newly diagnosed SLE who developed a linear, blistering rash on one hand and forearm that clinically looked like textbook herpes zoster. Biopsy and immunologic testing revealed it was actually bullous lupus, a skin manifestation of SLE itself.10PubMed. Localized linear bullous eruption of systemic lupus erythematosus in a child
This matters for two reasons. First, the treatments are completely different: shingles requires antivirals, while bullous lupus requires adjustment of immunosuppressive therapy. Second, a misdiagnosis of shingles might prompt a doctor to reduce immunosuppression (thinking the patient is over-suppressed), when the real problem is that lupus is under-controlled. If you develop a blistering, painful rash and have lupus, getting a definitive diagnosis through testing rather than visual impression alone is worth the effort.
Vaccination Changes the Calculus
The recombinant zoster vaccine (sold as Shingrix) has changed shingles prevention for lupus patients. Unlike the older live vaccine, it contains no live virus, so it can be given safely to people on immunosuppressive therapy. In a randomized, double-blind trial of lupus patients, 98 percent of those who received the vaccine developed a measurable antibody response. The vaccine did not trigger lupus flares: disease activity scores and flare rates were similar between vaccinated and placebo groups.11The Lancet Rheumatology. Immunogenicity and safety of the adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus
A larger real-world study using U.S. insurance claims confirmed that vaccinated SLE patients did not experience higher rates of severe lupus flares compared to unvaccinated patients.12RMD Open. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus The fear that vaccination itself might destabilize lupus, which was a legitimate concern with the older live vaccine, appears unfounded with the recombinant version.
Timing matters, though. Guidelines for patients with immune-mediated diseases recommend getting vaccinated at least two weeks before starting immunosuppressive therapy when possible, to give the immune system its best shot at mounting a strong response. For patients already on treatment, vaccination should go ahead anyway: the recommendation is not to interrupt immunosuppressive therapy for vaccination. The one exception is rituximab, a B-cell depleting drug. For patients on rituximab, vaccination should ideally happen at least five months after the last dose and at least four weeks before the next one, to allow enough B cells to recover for a vaccine response.13PubMed Central. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies
Despite the strong safety and immunogenicity data, vaccination rates in lupus patients remain low. Many patients and even some rheumatologists remain cautious about vaccinating immunosuppressed patients, a hesitation rooted in the era of live vaccines that has not caught up with the reality of the newer recombinant product.
Children with Lupus Face Even Steeper Odds
Shingles in childhood is uncommon enough to raise eyebrows in a pediatric clinic, but in children with lupus, it happens at striking rates. One study of 49 children with SLE recorded an incidence of about 59 episodes per 1,000 patient-years, far higher than the adult SLE rates described earlier. Most episodes occurred within six months of either the initial lupus diagnosis or a disease flare, and children who developed shingles were significantly more likely to have had other serious infections as well.14PubMed. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors
A larger study of 388 pediatric SLE patients found the prevalence of herpes zoster at about 16 percent, with kidney involvement more common in those who developed shingles. The drugs that predicted shingles in children were the same ones flagged in adults: glucocorticoids at doses of 5 mg or more (which carried a ten-fold increased risk), azathioprine, and intravenous cyclophosphamide.15PubMed Central. Incidence and risk factors of herpes zoster infection in pediatric systemic lupus erythematosus The recurrence rate in the pediatric group was about 16 percent, double the rate seen in adult studies.
For families, a shingles episode in a child with lupus can be alarming partly because it signals deeper immunosuppression. Pediatric rheumatologists often view a shingles episode as a clinical marker suggesting the immune system is under substantial pressure, whether from the disease itself or its treatment.
The Healthcare Cost You Do Not Expect
A shingles episode in someone with lupus does not just add the direct cost of antiviral treatment. It drives a measurable spike in overall healthcare use. In the month after a shingles diagnosis, SLE patients averaged about 45 percent more outpatient visits, more than double the emergency department visits, and roughly 40 percent more prescription fills compared to SLE patients without shingles. The average costs in the month after shingles were about $4,400 versus $3,000 for lupus patients without the infection, and the gap persisted at three months.16Arthritis & Rheumatology. Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Some of that cost likely reflects the flare-triggering effect described earlier. When shingles destabilizes lupus, the resulting flare demands its own workup and treatment. You end up managing two overlapping problems simultaneously, each complicating the other. For patients dealing with lupus-related financial strain, which is common given the disease’s tendency to affect younger working-age adults, an avoidable shingles episode can be a genuine economic blow.
Stress, Triggers, and What Remains Uncertain
Patients often ask whether stress can trigger shingles. Physical trauma and psychological stress have both been proposed as triggers for varicella-zoster virus reactivation, and it is a reasonable hypothesis given what we know about stress hormones and immune function. However, a narrative review that examined this question concluded that statistical evidence does not yet demonstrate that psychological stress alone can trigger shingles.17Tungs’ Medical Journal. The newest point in the treatment and prevention of herpes zoster: A narrative review For lupus patients, who are often under substantial psychological stress from managing a chronic illness, this is a complicated message. Stress may contribute, but the stronger and better-documented risk factors remain immunosuppression, lymphopenia, and disease activity.
What remains genuinely unsettled is how much of the shingles risk in lupus would persist if you could somehow treat the disease without immunosuppressive drugs. The study that isolated SLE patients with no other immune-compromising conditions and found a rate of about 14 per 1,000 patient-years (versus roughly 6 per 1,000 in the general population) suggests the disease itself carries substantial risk independent of treatment.1PubMed Central. Burden of herpes zoster among patients with systemic lupus erythematosus in the USA But those patients were still on some form of therapy, and fully untreated lupus is so rare in modern medicine that a clean comparison is essentially impossible. The practical answer is that both the disease and its treatment matter, and preventing shingles requires addressing both.